Wilmington Savings Fund Society FSB Has $109,000 Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Wilmington Savings Fund Society FSB decreased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 85.8% in the fourth quarter, HoldingsChannel reports. The firm owned 2,500 shares of the company’s stock after selling 15,167 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Revolution Medicines were worth $109,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC boosted its position in shares of Revolution Medicines by 55.8% in the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock valued at $28,000 after purchasing an additional 222 shares during the period. Captrust Financial Advisors boosted its position in shares of Revolution Medicines by 4.1% in the 3rd quarter. Captrust Financial Advisors now owns 8,459 shares of the company’s stock valued at $384,000 after purchasing an additional 337 shares during the period. KBC Group NV boosted its position in shares of Revolution Medicines by 12.9% in the 3rd quarter. KBC Group NV now owns 3,221 shares of the company’s stock valued at $146,000 after purchasing an additional 368 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Revolution Medicines by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,041 shares of the company’s stock valued at $267,000 after purchasing an additional 1,115 shares during the period. Finally, Quarry LP acquired a new stake in Revolution Medicines during the 3rd quarter worth about $82,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $41.32 on Friday. The stock’s 50 day simple moving average is $43.21 and its 200 day simple moving average is $46.42. Revolution Medicines, Inc. has a twelve month low of $28.43 and a twelve month high of $62.40. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of -11.51 and a beta of 1.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on RVMD shares. Wedbush restated an “outperform” rating and set a $70.00 price objective on shares of Revolution Medicines in a research report on Monday, December 2nd. HC Wainwright raised their price objective on Revolution Medicines from $64.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. raised their price objective on Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 3rd. Oppenheimer raised their price objective on Revolution Medicines from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. Finally, Piper Sandler raised their price objective on Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Revolution Medicines has a consensus rating of “Buy” and a consensus target price of $66.25.

Insider Activity at Revolution Medicines

In related news, CFO Jack Anders sold 2,635 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $45.40, for a total value of $119,629.00. Following the transaction, the chief financial officer now directly owns 96,470 shares of the company’s stock, valued at approximately $4,379,738. This trade represents a 2.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thilo Schroeder acquired 1,304,347 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was bought at an average cost of $46.00 per share, for a total transaction of $59,999,962.00. Following the completion of the purchase, the director now directly owns 2,096,612 shares in the company, valued at $96,444,152. This represents a 164.64 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 18,678 shares of company stock valued at $847,981. Corporate insiders own 8.00% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.